Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548772 | 0.86 | GABRA1 (0.50) | SMN1; SMN2LPAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL6441557 | 0.86 | SMN1; SMN2 (0.42) | NFE2L2SMN1; SMN2LPAR1MEN1KMT2A | |
| SCHEMBL16958800 | 0.83 | SMN1; SMN2 (0.44) | NFE2L2SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL4100987 | 0.83 | SMN1; SMN2 (0.44) | NFE2L2SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL27661726 | 0.83 | SMN1; SMN2 (0.44) | NFE2L2SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL15750738 | 0.83 | SMN1; SMN2 (0.44) | NFE2L2SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL2252742 | 0.83 | SMN1; SMN2 (0.44) | NFE2L2SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL12331440 | 0.83 | SMN1; SMN2 (0.44) | NFE2L2SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL670715 | 0.83 | MEN1 (0.49) | NFE2L2SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL3979394 | 0.83 | SMN1; SMN2 (0.44) | NFE2L2SMN1; SMN2MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715680-A | The method for preparing high-cis -1,4- polydiene with the carbon monoxide-olefin polymeric based on lanthanide series | 株式会社普利司通 | 2019-05-03 | — | — | CN | claimed |
| CN-104744243-B | (E)-2-phenyl-3-(3,5-dimethoxy-4 '-isopropyl benzene) purification method of propenoic acid | HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-04-06 | — | — | CN | claimed |
| EP-1177190-B1 | USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI CHEM PHARM (IT) | 2005-11-02 | — | — | EP | claimed |
| JP-2002544158-A | — | — | 2002-12-24 | — | — | JP | claimed |
| US-20020161009-A1 | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | RECORDATI S.A. | 2002-10-31 | — | — | US | claimed |
| EP-1177190-A2 | USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-02-06 | — | — | EP | claimed |
| US-6303606-B1 | FOR THERAPY OF SEXUAL DISORDERS | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2001-10-16 | — | — | US | claimed |
| WO-2000067735-A2 | USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2000-11-16 | — | — | WO | claimed |
| US-11912736-B2 | Diaryl trehalose compounds and uses thereof | THE UNIVERSITY OF MONTANA (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | OSAKA UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-5780675-A | NONCYTOTOXIC; SAPONIFICATION, CYCLIZATION, REDUCTION, REHYDRATION; CATALYTIC HYDROGENOLYSIS | THE UNIVERSITY OF NEW MEXICO (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0310126-B1 | DERIVATIVES OF PYROCATECHOL-CARBOXYLIC ACID, THEIR PREPARATION AND USE AS ACTIVE INGREDIENTS IN MEDICINES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-08-18 | — | — | EP | disclosed |
| US-5191108-A | Lipoxygenase inhibitors, antiinflammatory agents | HOFFMANN-LA ROCHE INC. (US) | 1993-03-02 | — | — | US | disclosed |
| US-5025036-A | Antiinflammatory agents, gastrointestinal, cardiovascular and skin disorders | HOFFMANN-LA ROCHE INC. (US) | 1991-06-18 | — | — | US | disclosed |
| US-4937373-A | Substituted naphthalene carboxylic acids | HOFFMANN-LA ROCHE INC. (US) | 1990-06-26 | — | — | US | disclosed |
| EP-0310126-A2 | Derivatives of pyrocatechol-carboxylic acid, their preparation and use as active ingredients in medicines | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161009-A1 | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | ADRA1B, ADRA2B, ADRB2 | NFE2L2 3591/4885SMN1; SMN2 1423/4885LPAR1 621/4885 |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | ESR1, ECE1, ESYT1 | NFE2L2 175/4885SMN1; SMN2 2387/4885LPAR1 3599/4885 |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | NFE2L2 1776/4885SMN1; SMN2 3640/4885LPAR1 3155/4885 |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | MAPK1, MAPK8, MAPK4 | NFE2L2 1776/4885SMN1; SMN2 3640/4885LPAR1 3155/4885 |
| US-11912736-B2 | Diaryl trehalose compounds and uses thereof | TREH, STT3B, DDOST | NFE2L2 2654/4885SMN1; SMN2 3675/4885LPAR1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.